Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies

Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of... Drug Saf (2017) 40:771–781 DOI 10.1007/s40264-017-0543-0 SYSTEMATIC REVIEW Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies 1,2,4 3 1,4,5 1,2,3,4 • • • • Lauren Hirsch Jaeun Yang Lauren Bresee Nathalie Jette 1,2,3,4 6 Scott Patten Tamara Pringsheim Published online: 5 June 2017 Springer International Publishing Switzerland 2017 Abstract metabolic outcome such as type 2 diabetes mellitus, dys- Introduction There is strong evidence from randomized lipidemia, obesity, hypertension, or metabolic syndrome. controlled trials (RCTs) that second-generation antipsy- Methods A systematic search process was used to identify chotic (SGA) medications are associated with metabolic studies for inclusion in this review. Included studies had to adverse events. However, with the recent increases in the be population-based studies of users of any SGA medica- use of SGAs worldwide and frequent off-label use, it is tion with at least one reported metabolic outcome. Study unclear whether these associations are generalizable to quality was also assessed using the AMSTAR tool, and populations beyond those included in RCTs. evidence was synthesized by both metabolic outcome and Objectives This review aims to characterize the impact of specific SGA medication. SGAs on the population through a systematic review of Results In total, 15 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drug Safety Springer Journals

Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies

Loading next page...
 
/lp/springer_journal/second-generation-antipsychotics-and-metabolic-side-effects-a-Il0sOYmNFv
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-5916
eISSN
1179-1942
D.O.I.
10.1007/s40264-017-0543-0
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial